| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 5.8 | GI50 | = | 5800 | nM |
| 9.6 | TGI | = | 9600 | nM |
| 17 | LC50 | = | 17000 | nM |
| 8.8 | GI50 | = | 8800 | nM |
| 19 | LC50 | = | 19000 | nM |
| 13 | TGI | = | 13000 | nM |
| Phenotype | Potency | Efficacy | Analysis Comment | Activity_Score | Curve_Description | Fit_LogAC50 | Fit_HillSlope | Fit_R2 | Fit_InfiniteActivity | Fit_ZeroActivity | Fit_CurveClass | Excluded_Points | Max_Response | Activity at 0.0000386857 uM | Activity at 0.0001060182 uM | Activity at 0.0001896372 uM | Activity at 0.0004510146 uM | Activity at 0.0007501981 uM | Activity at 0.0009728036 uM | Activity at 0.00288 uM | Activity at 0.00508 uM | Activity at 0.00871 uM | Activity at 0.015 uM | Activity at 0.026 uM | Activity at 0.053 uM | Activity at 0.079 uM | Activity at 0.232 uM | Activity at 0.457 uM | Activity at 0.692 uM | Activity at 1.068 uM | Activity at 2.292 uM | Activity at 3.859 uM | Activity at 11.39 uM | Activity at 17.02 uM | Activity at 25.62 uM | Activity at 57.25 uM | Activity at 87.55 uM | Activity at 183.4 uM | Activity at 286.0 uM | Compound QC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inactive | 0 | -6.75 | 4.9549 | 0.9727 | 0.0901 | 17.5 | 4 | 0 0 0 1 | 8.9408 | 15.9527 | -1.5916 | 1.4969 | 8.9408 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Inactive | 0 | -5.3 | 4.095 | 0.9996 | 5.5 | -7.7823 | 4 | 0 0 0 1 | -11.1081 | -7.5736 | -7.7353 | 5.034 | -11.1081 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Inactive | 0 | -5.15 | 4.9549 | 0.907 | -15.9207 | 9.5 | 4 | 0 0 0 1 | 17.8725 | 5.2874 | 13.9021 | -13.6839 | 17.8725 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Activator | 35.4813 | 46.4095 | 0 | Single point of activity | -4.45 | 2.5884 | 1 | 45.9404 | -0.4691 | 3 | 1 0 0 0 | 35.593 | 40.1678 | -0.3909 | 1.933 | 35.593 | QC'd by Sytravon | |||||||||||||||||||||||
| Activator | 39.8107 | 72.2646 | 0 | Single point of activity | -4.4 | 4.9549 | 0.9515 | 68.1912 | -4.0733 | 3 | 0 0 0 0 | 58.0117 | 5.8738 | -9.2278 | -8.5224 | 58.0117 | QC'd by Sytravon | |||||||||||||||||||||||
| Activator | 14.1254 | 45.3319 | 0 | Partial curve; partial efficacy; poor fit | -4.85 | 2.4064 | 0.9982 | 40.7728 | -4.5591 | 2.4 | 1 0 0 0 | 40.0933 | -24.9557 | -3.8845 | 11.5254 | 40.0933 | QC'd by Sytravon | |||||||||||||||||||||||
| Inactive | 0 | -5.75 | 4.9549 | 0.9291 | -20.6086 | 33.1545 | 4 | 1 0 0 0 | -12.8464 | 45.4569 | 28.2161 | -28.42 | -12.8464 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Inactive | 0 | -4.35 | 4.9549 | 0.855 | -24.2184 | -0.5 | 4 | 0 0 0 0 | -18.932 | -3.6477 | -2.409 | 4.988 | -18.932 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Inactive | 0 | -4.7 | 3.6272 | 0.8625 | 15 | -8.5523 | 4 | 0 0 0 0 | 14.477 | -2.951 | -13.7936 | -5.9646 | 14.477 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Inactive | 0 | -6.7 | 4.9549 | 0.6637 | 3 | -16.864 | 4 | 0 0 0 0 | 8.8169 | -15.72 | 6.3794 | -6.3599 | 8.8169 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Inactive | 0 | -4.75 | 2.4064 | 0.9999 | 21.5 | -2.4101 | 4 | 1 0 0 0 | 20.2184 | 33.3778 | -2.4251 | 3.5771 | 20.2184 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Inactive | 0 | -4.4 | 4.9549 | 0.8117 | 2.5 | -8.345 | 4 | 0 0 0 0 | 1.096 | -8.966 | -5.5054 | -11.1209 | 1.096 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Activator | 39.8107 | 38.7945 | 0 | Single point of activity | -4.4 | 4.9549 | 0.6241 | 41.7557 | 2.9612 | 3 | 0 0 0 0 | 36.2039 | 21.355 | -6.3904 | -4.5325 | 36.2039 | QC'd by Sytravon | |||||||||||||||||||||||
| Inactive | 0 | -6.05 | 4.095 | 0.9994 | -6.0518 | 20 | 4 | 0 0 0 1 | 20.5156 | 19.7377 | 1.4122 | -6.2932 | 20.5156 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Inactive | 0 | -5.2 | 4.095 | 1 | 10.5 | -10.1683 | 4 | 1 0 0 1 | -15.9884 | 36.1362 | -10.1402 | 8.7939 | -15.9884 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Inactive | 0 | -6.5 | 1.3905 | 0.9999 | -24.241 | 0.2745 | 4 | 0 0 0 1 | -5.5981 | -4.3546 | -20.7587 | -23.9509 | -5.5981 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Inactive | 0 | -6.8 | 4.9549 | 0.711 | -2.4459 | 21 | 4 | 0 0 0 0 | -3.3453 | 17.3219 | -9.9549 | 5.5495 | -3.3453 | QC'd by Sytravon | ||||||||||||||||||||||||||
| Activator | 39.8107 | 47.809 | 0 | Partial curve; partial efficacy; poor fit | -4.4 | 4.9549 | 0.5212 | 50.2399 | 2.4309 | 2.4 | 0 0 0 0 | 43.4722 | 30.2363 | -10.9855 | -11.5143 | 43.4722 | QC'd by Sytravon | |||||||||||||||||||||||
| Activator | 22.3872 | 75.5081 | 0 | Partial curve; high efficacy; poor fit | -4.65 | 1.9673 | 0.9829 | 96.5324 | 21.0243 | 2.3 | 0 0 0 0 | 86.4985 | 26.0932 | 16.3365 | 36.2613 | 86.4985 | QC'd by Sytravon | |||||||||||||||||||||||
| Inactive | 0 | -6.8 | 4.9549 | 0.7429 | -1 | -13.0738 | 4 | 0 0 0 0 | 1.8063 | -11.3115 | 0.8702 | -5.1757 | 1.8063 | QC'd by Sytravon |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 7.2 | GI50 | = | 7200 | nM |
| 19 | LC50 | = | 19000 | nM |
| 12 | TGI | = | 12000 | nM |
| 41 | LC50 | = | 41000 | nM |
| 17 | GI50 | = | 17000 | nM |
| 27 | TGI | = | 27000 | nM |
| Activation at 3 uM |
|---|
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| -1.07 |
| Phenotype-Replicate_1 | Potency-Replicate_1 | Efficacy-Replicate_1 | Analysis Comment-Replicate_1 | Activity_Score-Replicate_1 | Curve_Description-Replicate_1 | Fit_LogAC50-Replicate_1 | Fit_HillSlope-Replicate_1 | Fit_R2-Replicate_1 | Fit_InfiniteActivity-Replicate_1 | Fit_ZeroActivity-Replicate_1 | Fit_CurveClass-Replicate_1 | Excluded_Points-Replicate_1 | Max_Response-Replicate_1 | Activity at 0.0000075213 uM-Replicate_1 | Activity at 0.0000171744 uM-Replicate_1 | Activity at 0.0000689059 uM-Replicate_1 | Activity at 0.0001619730 uM-Replicate_1 | Activity at 0.0003751800 uM-Replicate_1 | Activity at 0.0007781017 uM-Replicate_1 | Activity at 0.00212 uM-Replicate_1 | Activity at 0.00657 uM-Replicate_1 | Activity at 0.017 uM-Replicate_1 | Activity at 0.038 uM-Replicate_1 | Activity at 0.085 uM-Replicate_1 | Activity at 0.191 uM-Replicate_1 | Activity at 0.435 uM-Replicate_1 | Activity at 1.330 uM-Replicate_1 | Activity at 4.074 uM-Replicate_1 | Activity at 10.46 uM-Replicate_1 | Activity at 23.64 uM-Replicate_1 | Activity at 52.95 uM-Replicate_1 | Activity at 115.2 uM-Replicate_1 | Activity at 299.6 uM-Replicate_1 | Activity at 1087.9 uM-Replicate_1 | Activity at 2306.0 uM-Replicate_1 | Activity at 5157.0 uM-Replicate_1 | Activity at 11530.0 uM-Replicate_1 | Activity at 25780.0 uM-Replicate_1 | Activity at 57660.0 uM-Replicate_1 | Compound QC-Replicate_1 | Phenotype-Replicate_2 | Potency-Replicate_2 | Efficacy-Replicate_2 | Analysis Comment-Replicate_2 | Activity_Score-Replicate_2 | Curve_Description-Replicate_2 | Fit_LogAC50-Replicate_2 | Fit_HillSlope-Replicate_2 | Fit_R2-Replicate_2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inactive | 0 | 0 | 0 | 4 | -3.5643 | -2.3504 | -2.9312 | -2.3657 | -2.8224 | -2.6018 | 0.0394 | 2.8539 | -0.9099 | -0.8614 | -3.0049 | -2.5808 | -0.7 | -3.5643 | QC'd by SIGMA | Inactive | 0 | ||||||||||||||||||||||||||||
| Inactive | 0 | 0 | 0 | 4 | -4.9449 | -1.1401 | -4.8828 | 1.7278 | 1.7167 | -2.1117 | -5.6964 | 0.3933 | 0.8939 | 0.1314 | -2.7335 | 3.195 | -4.9521 | -4.9449 | QC'd by SIGMA | Inactive | 0 | ||||||||||||||||||||||||||||
| Inactive | 0 | 0 | 0 | 4 | 2.7107 | -2.1884 | 1.3985 | 1.4582 | 0.7693 | -2.4787 | 1.52 | 2.8986 | 0.9702 | -0.0253 | 2.1293 | 2.7766 | 1.539 | 2.7107 | QC'd by Enamine | Inactive | 0 | ||||||||||||||||||||||||||||
| Inactive | 0 | 0 | 0 | 4 | -2.1522 | -2.3143 | -3.894 | -2.3698 | 3.0635 | -2.9724 | -0.698 | 1.807 | -0.3874 | -2.2387 | 0.0851 | -4.1965 | 3.0171 | -2.1522 | QC'd by SIGMA | Inactive | 0 | ||||||||||||||||||||||||||||
| Inactive | 0 | -4.3489 | 2.2526 | 0.8543 | -15.2749 | -1.5 | 4 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -14.3957 | -1.8486 | -1.8251 | -1.3415 | -0.2999 | -5.8043 | -1.4625 | 0.152 | 0.0394 | -2.6869 | -2.4228 | -2.2664 | -9.6519 | -14.3957 | QC'd by SIGMA | Inactive | 0 | -4.0989 | 2.1876 | 0.881 | |||||||||||||||||||||
| Inactive | 0 | -4.3989 | 1.3443 | 0.8661 | -18.2112 | -1 | 4 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -16.0093 | -2.3466 | 0.8145 | 0.3878 | -0.5249 | -2.2045 | -0.0596 | -0.3675 | -2.1137 | -2.5302 | -0.6582 | -8.8446 | -8.7305 | -16.0093 | QC'd by Acros | Inactive | 0 | -4.1989 | 1.6266 | 0.9372 | |||||||||||||||||||||
| Inactive | 0 | -4.3713 | 1.331 | 0.7782 | -33.4439 | -3.503 | 4 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -29.5366 | -4.0189 | -0.7745 | -2.4487 | -0.7353 | -13.4714 | -1.9963 | -2.0808 | -1.5803 | -2.9931 | -5.0804 | -13.0346 | -7.2628 | -16.8143 | -29.5366 | QC'd by LightBiologicals | Inactive | 0 | -4.3713 | 1.2221 | 0.9463 | ||||||||||||||||||||
| Inactive | 0 | -4.1489 | 1.6266 | 0.9461 | -28.1716 | -1 | 4 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -20.143 | -1.7608 | -0.2388 | 0.2248 | 0.5264 | -2.4986 | -0.1313 | -2.2365 | -0.2423 | -3.4362 | -3.0971 | -3.2181 | -11.2156 | -20.143 | QC'd by Enamine | Inhibitor | 79.6407 | 31.4916 | 10 | Partial curve; partial efficacy; poor fit | -4.0989 | 2.5884 | 0.988 | ||||||||||||||||||
| Inhibitor | 79.6407 | 37.8784 | 10 | Partial curve; partial efficacy; poor fit | -4.0989 | 2.3332 | 0.6037 | -41.3784 | -3.5 | -2.4 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -31.1486 | 0.0477 | -0.2424 | -0.1109 | -17.1482 | -2.6043 | 0.0987 | 1.3021 | -8.8121 | -0.6811 | -2.6079 | -6.0005 | -11.8578 | -31.1486 | QC'd by LightBiologicals | Inhibitor | 70.9799 | 33.8113 | 10 | Partial curve; partial efficacy; poor fit | -4.1489 | 1.4787 | 0.9532 | |||||||||||||||
| Inactive | 0 | -4.1489 | 1.331 | 0.6595 | -35.6335 | -1 | 4 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -26.3612 | 1.8269 | -1.2651 | 2.0528 | -1.3342 | -1.1508 | -1.3078 | -0.329 | -8.1235 | 0.9213 | -0.3901 | -8.3475 | -13.4823 | -26.3612 | QC'd by LightBiologicals | Inhibitor | 63.2609 | 40.7162 | 21 | Partial curve; partial efficacy | -4.1989 | 1.5579 | 0.9889 | ||||||||||||||||||
| Inhibitor | 31.7055 | 100.2192 | 40 | Partial curve; high efficacy | -4.4989 | 1.4163 | 0.9793 | -102.2947 | -2.0755 | -2.1 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -88.7975 | 1.5993 | 1.9578 | -0.4182 | -5.9156 | -12.3257 | -6.8125 | 0.6301 | -0.9357 | -7.8675 | -21.9718 | -39.1747 | -68.2733 | -88.7975 | QC'd by SIGMA | Inhibitor | 28.2576 | 108.4027 | 40 | Partial curve; high efficacy | -4.5489 | 1.2475 | 0.9984 | |||||||||||||||
| Inactive | 0 | -4.4489 | 1.5386 | 0.9285 | -23.7863 | 1 | 4 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -21.4885 | 2.5819 | 2.144 | -0.9228 | 1.5778 | 0.3813 | -0.7273 | -0.0178 | 0.4803 | 2.4385 | -0.728 | -9.9293 | -11.8247 | -21.4885 | QC'd by SIGMA | Inactive | 0 | -4.3989 | 1.6259 | 0.9598 | |||||||||||||||||||||
| Inhibitor | 9.3337 | 39.8967 | 21 | Complete curve; partial efficacy | -5.0299 | 2.0437 | 0.9899 | -39.8967 | 0 | -1.2 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -36.3129 | -0.2423 | -0.4463 | -0.2999 | 0.6478 | 0.3636 | 1.006 | -0.4987 | 1.2825 | -1.1546 | -7.8589 | -17.895 | -35.8398 | -36.3129 | QC'd by LightBiologicals | Inhibitor | 11.7504 | 56.3884 | 21 | Partial curve; partial efficacy | -4.9299 | 1.111 | 0.9845 | |||||||||||||||
| Inhibitor | 31.7055 | 101.4573 | 40 | Partial curve; high efficacy | -4.4989 | 1.111 | 0.9982 | -102.7597 | -1.3024 | -2.1 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -82.349 | -1.7206 | -3.1014 | -1.0307 | -0.462 | -0.0614 | -0.5481 | -3.1286 | -4.6801 | -13.1432 | -23.5612 | -42.1146 | -67.192 | -82.349 | QC'd by SIGMA | Inhibitor | 25.1846 | 89.5091 | 40 | Partial curve; high efficacy | -4.5989 | 1.3723 | 0.9943 | |||||||||||||||
| Inactive | 0 | -4.3989 | 1.3723 | 0.9408 | -30.7143 | -1.5 | 4 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -27.2619 | -3.9038 | -4.2597 | 0.9522 | 0.2767 | -0.086 | -3.7725 | -0.0863 | -0.3476 | -4.4856 | -5.6587 | -11.4378 | -17.5999 | -27.2619 | QC'd by Enamine | Inactive | 0 | -4.3989 | 1.3723 | 0.9104 | |||||||||||||||||||||
| Inhibitor | 0.02 | 91.5374 | 95 | Complete curve; high efficacy | -7.6989 | 1.21 | 0.9985 | -95.5053 | -3.9679 | -1.1 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -96.9758 | -10.1145 | -26.2532 | -42.3865 | -67.4835 | -79.9456 | -90.8539 | -91.593 | -94.2489 | -95.4721 | -96.0956 | -96.1267 | -97.0582 | -96.9758 | QC'd by SIGMA | Inhibitor | 0.1416 | 94.8402 | 91 | Complete curve; high efficacy | -6.8489 | 1.21 | 0.9987 | |||||||||||||||
| Inhibitor | 70.9799 | 57.4014 | 21 | Partial curve; partial efficacy | -4.1489 | 1.4641 | 0.9678 | -60.4859 | -3.0846 | -2.2 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -45.8227 | -1.5241 | -1.1304 | -2.119 | -3.4583 | -2.7138 | -4.9163 | -1.3699 | -5.0741 | -7.7268 | -8.2608 | -10.3758 | -24.1789 | -45.8227 | QC'd by TCI | Inhibitor | 63.2609 | 59.3706 | 21 | Partial curve; partial efficacy | -4.1989 | 1.8265 | 0.9826 | |||||||||||||||
| Inhibitor | 31.7055 | 88.4583 | 40 | Partial curve; high efficacy | -4.4989 | 1.2475 | 0.9907 | -90.0614 | -1.6031 | -2.1 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -73.0646 | -2.1792 | -0.7242 | -0.9217 | -2.0267 | -1.1711 | -1.4022 | -1.5555 | -4.0648 | -12.1704 | -19.1709 | -32.2561 | -64.0802 | -73.0646 | QC'd by SIGMA | Inhibitor | 31.7055 | 86.8385 | 40 | Partial curve; high efficacy | -4.4989 | 1.111 | 0.9934 | |||||||||||||||
| Inhibitor | 7.098 | 99.9448 | 83 | Complete curve; high efficacy | -5.1489 | 1.3443 | 0.9949 | -102.6257 | -2.681 | -1.1 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -98.8687 | -2.2636 | -1.9377 | -0.2674 | -0.3864 | -3.2139 | -8.5636 | -4.0834 | -14.5383 | -36.543 | -60.2337 | -91.3595 | -96.848 | -98.8687 | QC'd by TCI | Inhibitor | 5.6381 | 99.0727 | 84 | Complete curve; high efficacy | -5.2489 | 1.6266 | 0.998 | |||||||||||||||
| Inhibitor | 14.1623 | 99.522 | 42 | Partial curve; high efficacy | -4.8489 | 0.7 | 0.9894 | -100.6417 | -1.1197 | -2.1 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -88.2822 | -1.4919 | -2.9847 | -0.2649 | -1.6478 | -3.8502 | -2.8959 | -7.6423 | -18.6375 | -36.1235 | -44.1844 | -53.91 | -71.7844 | -88.2822 | QC'd by SIGMA | Inhibitor | 17.8293 | 95.7742 | 81 | Complete curve; high efficacy | -4.7489 | 1.21 | 0.9995 |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 6 | GI50 | = | 6000 | nM |
| 27 | LC50 | = | 27000 | nM |
| 14 | TGI | = | 14000 | nM |
| 6.9 | GI50 | = | 6900 | nM |
| 18 | LC50 | = | 18000 | nM |
| 11 | TGI | = | 11000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 8.4 | LC50 | = | 8400 | nM |
| 3.8 | GI50 | = | 3800 | nM |
| 5.7 | TGI | = | 5700 | nM |
| 9.7 | LC50 | = | 9700 | nM |
| 3.7 | GI50 | = | 3700 | nM |
| 6 | TGI | = | 6000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 7.5 | LC50 | = | 7500 | nM |
| 4.5 | GI50 | = | 4500 | nM |
| 5.8 | TGI | = | 5800 | nM |
| 9.2 | GI50 | = | 9200 | nM |
| 19 | LC50 | = | 19000 | nM |
| 13 | TGI | = | 13000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 5.3 | GI50 | = | 5300 | nM |
| 7.7 | TGI | = | 7700 | nM |
| 12 | LC50 | = | 12000 | nM |
| 30 | LC50 | = | 30000 | nM |
| 13 | GI50 | = | 13000 | nM |
| 19 | TGI | = | 19000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 5.5 | GI50 | = | 5500 | nM |
| 7.8 | TGI | = | 7800 | nM |
| 11 | LC50 | = | 11000 | nM |
| 9 | GI50 | = | 9000 | nM |
| 21 | LC50 | = | 21000 | nM |
| 14 | TGI | = | 14000 | nM |
| Activation at 3 uM |
|---|
| 9.75 |
| 9.75 |
| 9.75 |
| 9.75 |
| 9.75 |
| 9.75 |
| 9.75 |
| 9.75 |
| 9.75 |
| 9.75 |
| 9.75 |
| 9.75 |
| 9.75 |
| 9.74 |
| 9.74 |
| 9.74 |
| 9.74 |
| 9.74 |
| 9.74 |
| 9.74 |
| Standard Type | Activity Comment |
|---|---|
| Activity | Active |
| Activity | Active |
| Standard Type | Activity Comment |
|---|---|
| Activity | Active |
| Activity | Active |
| Standard Type | Standard Relation | Standard Value |
|---|---|---|
| Ratio | = | 0.53 |
| Ratio | = | 0.81 |
| Ratio | = | 0.34 |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Inhibition | % | Active |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Tm | = | 62 | degrees C |
| Standard Type | Standard Relation | Standard Value |
|---|---|---|
| Ratio | = | 0.26 |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Tm | = | 65 | degrees C |
| Phenotype | Potency | Efficacy | Analysis Comment | Activity_Score | Curve_Description | Fit_LogAC50 | Fit_HillSlope | Fit_R2 | Fit_InfiniteActivity | Fit_ZeroActivity | Fit_CurveClass | Excluded_Points | Max_Response | Activity at 0.0001000000 uM | Activity at 0.0003000000 uM | Activity at 0.0006116734 uM | Activity at 0.00133 uM | Activity at 0.00297 uM | Activity at 0.00673 uM | Activity at 0.015 uM | Activity at 0.033 uM | Activity at 0.075 uM | Activity at 0.167 uM | Activity at 0.369 uM | Activity at 0.412 uM | Activity at 0.836 uM | Activity at 1.842 uM | Activity at 2.061 uM | Activity at 4.179 uM | Activity at 9.216 uM | Activity at 20.61 uM | Activity at 46.08 uM | Activity at 92.17 uM | Compound QC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inactive | 0 | 4.095 | 0.5622 | -0.5 | -17.4055 | 4 | 1 0 0 0 0 0 1 0 0 0 0 0 0 0 | 4.0358 | -8.1088 | -16.5879 | -0.7265 | -5.6584 | 4.373 | 0.1327 | -9.7032 | 0.3685 | 4.1527 | -0.141 | -3.5272 | -0.9713 | -9.3203 | 4.0358 | QC'd by NIEHS/NTP | |||||||||||
| Activator | 15.8489 | 52.3975 | 0 | Single point of activity | -4.8 | 0.4 | 0.5108 | 48.9806 | -3.4169 | 3 | 0 0 0 0 0 1 0 0 0 0 0 1 0 1 0 | 38.0621 | 2.0116 | -8.9739 | -7.0623 | 0 | -7.0944 | -39.2396 | 0 | 18.7338 | 25.7808 | 0 | 0 | -59.5394 | 11.6237 | 48.2153 | 38.0621 | QC'd by NIEHS | ||||||
| Inactive | 0 | 4 | -1.0832 | -10.8974 | 1.0031 | -11.058 | -11.888 | 3.6568 | 0.9182 | 5.3174 | 0.029 | -1.4893 | 2.1711 | 3.0788 | -19.8367 | -2.8584 | -1.0832 | QC'd by NIEHS/NTP | ||||||||||||||||
| Inactive | 0 | 4 | 2.4598 | 2.223 | -1.6367 | 8.778 | -0.1138 | 9.2269 | 3.4407 | 11.6742 | -2.1465 | 11.8823 | -1.8078 | -2.083 | 3.7825 | 4.4909 | 2.4598 | QC'd by NIEHS | ||||||||||||||||
| Inactive | 0 | 1.8579 | 0.4575 | 4.5 | -21.0899 | 4 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 12.886 | -15.9083 | 0.1018 | 0.3771 | -0.0246 | 7.9993 | -3.797 | 13.0973 | 11.6372 | 8.3022 | -2.6663 | 9.3202 | -2.3421 | -0.2854 | 12.886 | QC'd by NIEHS/NTP | |||||||||||
| Inactive | 0 | 4.9549 | 0.5492 | -6.7707 | 1.5 | 4 | 0 0 0 0 0 0 0 0 0 0 1 0 0 1 | 1.3669 | -1.0856 | -0.7765 | 1.1242 | 1.7058 | 0.7901 | -1.9869 | 6.0901 | 5.2659 | 3.2331 | -7.9279 | -28.3694 | -1.3017 | -10.2255 | 1.3669 | QC'd by NIEHS/NTP | |||||||||||
| Inactive | 0 | 4 | -5.5826 | -4.0359 | -4.4476 | -11.3473 | -11.9097 | -1.5507 | -10.1535 | -3.3626 | 1.3234 | -0.4426 | -13.9824 | -5.2512 | -18.0387 | -15.3022 | -5.5826 | QC'd by NIEHS/NTP | ||||||||||||||||
| Inhibitor | 39.8107 | 51.9004 | 20 | Partial curve; partial efficacy | -4.4 | 3.99 | 0.9828 | -50.1381 | 1.7623 | -2.2 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | -49.4594 | 3.1993 | -0.0269 | 2.7134 | -1.9807 | 5.2946 | 0.2133 | -0.1387 | -0.2625 | 2.4708 | 0.1777 | 2.5372 | 0.4925 | -30.4729 | -49.4594 | QC'd by NIEHS/NTP | |||||||
| Inactive | 0 | 2.3332 | 0.6977 | -10.8456 | 1 | 4 | 0 0 0 0 0 0 1 0 0 0 0 1 0 1 | -1.1266 | -1.4611 | 1.2528 | -0.0369 | 0.0295 | 5.5889 | -3.0357 | 6.7506 | 4.5747 | -1.4797 | -0.1821 | -9.6414 | -1.4402 | -9.8713 | -1.1266 | QC'd by NIEHS/NTP | |||||||||||
| Inactive | 0 | 4 | 14.6008 | 0.5397 | -1.6708 | -0.413 | 0.9694 | 7.4259 | -2.2585 | 5.0869 | 7.9351 | -2.4752 | -5.636 | 5.3996 | 1.849 | -2.4871 | 14.6008 | QC'd by NIEHS/NTP | ||||||||||||||||
| Inactive | 0 | 0.7 | 0.5791 | -8.9231 | 4 | 4 | 0 0 0 0 0 0 1 0 0 0 0 0 0 1 | 2.8063 | 3.5153 | 5.1938 | 1.4116 | 6.3363 | 4.61 | 2.7429 | 12.4401 | 6.0481 | -0.1411 | 0.3707 | -1.4781 | 2.4968 | -5.7693 | 2.8063 | QC'd by NIEHS/NTP | |||||||||||
| Inactive | 0 | 4 | -17.8369 | -10.5115 | -2.5586 | -8.8158 | -26.0957 | -0.4819 | -9.7892 | -2.0149 | 0.2733 | 2.7166 | -17.2183 | -0.4759 | 1.0932 | -12.7028 | -17.8369 | QC'd by NIEHS/NTP | ||||||||||||||||
| Inactive | 0 | 4.9549 | 0.4427 | -9.7222 | -1.5 | 4 | 1 0 1 0 0 0 0 0 0 0 0 0 0 0 | -13.1018 | -5.5392 | 0.0068 | 7.7337 | 0.4588 | 4.0455 | -12.3759 | -6.5724 | 0.9218 | 1.9145 | -11.3469 | -7.6261 | -8.5179 | -8.6226 | -13.1018 | QC'd by NIEHS/NTP | |||||||||||
| Inactive | 0 | 3.132 | 0.7434 | -16.0784 | 1.5 | 4 | 0 0 0 0 0 0 0 0 0 0 0 0 0 1 | 3.9965 | 3.3921 | -1.1556 | 1.9715 | 2.0177 | 3.8894 | -2.609 | 2.8757 | 2.7238 | 4.1025 | -3.5446 | 2.1635 | -3.6983 | -12.982 | 3.9965 | QC'd by NIEHS/NTP | |||||||||||
| Inactive | 0 | 4 | 7.5372 | 4.3881 | -20.2011 | 5.5178 | -1.3758 | 2.0045 | -1.4401 | 4.9593 | -2.1122 | 1.3726 | -3.0011 | -3.0677 | 1.1883 | 2.1817 | 7.5372 | QC'd by NIEHS/NTP | ||||||||||||||||
| Inactive | 0 | 4 | 11.4525 | 0.2692 | -0.1403 | -0.3748 | -11.7489 | 2.8347 | -5.0546 | 16.8984 | 0.05 | 13.829 | -3.6094 | -0.5197 | 8.0326 | -1.5476 | 11.4525 | QC'd by NIEHS/NTP | ||||||||||||||||
| Inactive | 0 | 4 | 9.9936 | 1.7139 | 7.1691 | 6.3352 | -0.3432 | 9.148 | -5.8673 | -1.5641 | 12.611 | 1.8237 | 8.2616 | -0.6654 | 1.7363 | 2.6319 | 9.9936 | QC'd by NIEHS/NTP | ||||||||||||||||
| Inactive | 0 | 4 | 10.234 | 0.5252 | 1.3877 | -1.9626 | -0.942 | 5.6494 | -0.2769 | 11.7052 | 8.376 | 6.8657 | -0.149 | -0.1944 | 2.6788 | -6.4192 | 10.234 | QC'd by NIEHS/NTP | ||||||||||||||||
| Activator | 22.3872 | 33.8938 | 0 | Complete curve; partial efficacy; poor fit | -4.65 | 2.2526 | 0.7151 | 33.9963 | 0.1025 | 1.4 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 25.5224 | 0.4272 | -0.9219 | -0.128 | -2.1061 | 8.1765 | -1.5863 | -10.2265 | 12.1648 | 6.8628 | -0.3193 | -6.5155 | 17.6087 | 32.2689 | 25.5224 | QC'd by NIEHS/NTP | |||||||
| Inactive | 0 | 4 | 9.9848 | 5.5826 | 0.0396 | -1.5504 | -1.3004 | 3.295 | 3.9882 | 12.2742 | 8.0646 | 9.1192 | 2.03 | 1.2922 | 7.4225 | -2.9974 | 9.9848 | QC'd by NIEHS/NTP |
| Phenotype | Potency | Efficacy | Analysis Comment | Curve_Description | Fit_LogAC50 | Fit_HillSlope | Fit_R2 | Fit_InfiniteActivity | Fit_ZeroActivity | Fit_CurveClass | Excluded_Points | Max_Response | Activity at 0.018 uM | Activity at 0.037 uM | Activity at 0.074 uM | Activity at 0.164 uM | Activity at 0.369 uM | Activity at 0.461 uM | Activity at 0.737 uM | Activity at 0.922 uM | Activity at 1.840 uM | Activity at 2.300 uM | Activity at 3.690 uM | Activity at 4.610 uM | Activity at 9.233 uM | Activity at 20.57 uM | Activity at 46.10 uM | Activity at 92.20 uM | Compound QC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inactive | 4 | 0 0 0 0 0 | 0.2596 | 10.769 | 4.1255 | -1.6909 | -0.7487 | 0.2596 | QC'd by "Chem Div" | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -0.8876 | -5.2018 | -3.6707 | 0.3303 | 2.9155 | -0.8876 | QC'd by "Chem Div" | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -4.2306 | -10.0984 | -0.7957 | -0.9322 | 2.0609 | -4.2306 | QC'd by "Chem Div" | ||||||||||||||||||||
| Inactive | 4 | 5.8218 | -1.6618 | -3.0553 | 9.7773 | -4.173 | 5.8218 | QC'd by "Chem Div" | |||||||||||||||||||||
| Inactive | 4 | -3.2651 | 11.605 | -17.8848 | 5.9785 | 14.3087 | -3.2651 | QC'd by "Chem Div" | |||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -7.241 | 3.2008 | 3.9728 | -4.5121 | 3.9811 | -7.241 | QC'd by "Chem Div" | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -9.807 | 8.9869 | 0.3484 | 0.3728 | 7.0197 | -9.807 | QC'd by "Chem Div" | ||||||||||||||||||||
| Cytotoxic | 17.7828 | 35.5846 | Partial curve; partial efficacy | -4.75 | 2.3031 | 0.9974 | -42.6167 | -7.0321 | -2.2 | 0 0 0 0 0 | -39.1036 | -6.2767 | -6.4175 | -8.2439 | -13.6777 | -39.1036 | QC'd by "Chem Div" | ||||||||||||
| Cytotoxic | 3.5481 | 40.0619 | Single point of activity | -5.45 | 4.9549 | 0.8999 | -40.3659 | -0.3039 | -3 | 0 0 0 0 1 | 2.6367 | -8.333 | 7.8061 | -1.7484 | -40.2332 | 2.6367 | QC'd by "Chem Div" | ||||||||||||
| Inactive | 4 | 0 0 0 0 1 | 0.5424 | 1.6591 | 9.6647 | 14.2749 | 15.5896 | 0.5424 | QC'd by "Chem Div" | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | 5.9628 | -8.298 | -2.3104 | 6.1361 | -3.4428 | 5.9628 | QC'd by "Chem Div" | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -1.0151 | -4.6247 | -5.8885 | -4.492 | -0.7127 | -1.0151 | QC'd by "Chem Div" | ||||||||||||||||||||
| Inactive | 4 | -0.9022 | -1.2889 | 13.9053 | -1.079 | 4.3101 | -0.9022 | QC'd by "Chem Div" | |||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -23.5202 | -1.5751 | 7.1469 | -12.6721 | 9.6037 | -23.5202 | QC'd by "Chem Div" | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 1 | -0.075 | -0.6173 | -0.8732 | 5.135 | 2.1913 | -0.075 | QC'd by "Chem Div" | ||||||||||||||||||||
| Cytotoxic | 35.4813 | 33.3813 | Single point of activity | -4.45 | 4.9549 | 0.4913 | -37.3813 | -4 | -3 | 0 0 0 0 0 | -30.3178 | -0.6381 | -23.6633 | -3.8386 | 6.0591 | -30.3178 | QC'd by "Chem Div" | ||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -17.414 | 0.1464 | -4.8771 | -5.0687 | -7.6162 | -17.414 | QC'd by "Chem Div" | ||||||||||||||||||||
| Inactive | 4 | -4.6673 | -7.1501 | -3.3264 | -4.1232 | -3.249 | -4.6673 | QC'd by "Chem Div" | |||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -17.3878 | 6.5726 | 2.9374 | -7.8375 | -3.1433 | -17.3878 | QC'd by "Chem Div" | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 1 | -10.2269 | -7.0609 | -5.5812 | -5.8217 | 2.0518 | -10.2269 | QC'd by "Chem Div" |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Not Active |
| Inhibition | % | Not Active |
| Standard Type | Standard Relation | Standard Value |
|---|---|---|
| Ratio | = | 0.47 |
| %Activity at 5 uM | Value | Mean Low | Std Deviation Low | Mean High | Std Deviation High |
|---|---|---|---|---|---|
| 17.7 | 1388986 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| -5.5 | 2023753 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| -1.9 | 1947331 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 4.9 | 1776516 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 4.4 | 1681435 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 7.1 | 1654104 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| -16.9 | 2220014 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 5.5 | 1825441 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| -10.2 | 2135725 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 13.1 | 1722580 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 0.1 | 1996001 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| -1.5 | 1994666 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 12.6 | 1687553 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| -12.4 | 2138337 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 1.9 | 1864558 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 14.3 | 1574274 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 20.4 | 1414289 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 67.4 | 531762 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 3.1 | 1778225 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| 53.5 | 823431 | 164067.88 | 8625.2 | 2080144.63 | 200104.91 |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Tm | = | 59 | degrees C |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Not Active |
| Inhibition | % | Not Active |
| Inhibition at 3 uM |
|---|
| 6.48 |
| 6.48 |
| 6.48 |
| 6.48 |
| 6.48 |
| 6.48 |
| 6.48 |
| 6.48 |
| 6.48 |
| 6.48 |
| 6.48 |
| 6.48 |
| 6.47 |
| 6.47 |
| 6.47 |
| 6.47 |
| 6.47 |
| 6.47 |
| 6.47 |
| 6.47 |
| Phenotype | Potency | Efficacy | Analysis Comment | Curve_Description | Fit_LogAC50 | Fit_HillSlope | Fit_R2 | Fit_InfiniteActivity | Fit_ZeroActivity | Fit_CurveClass | Excluded_Points | Max_Response | Activity at 0.018 uM | Activity at 0.037 uM | Activity at 0.074 uM | Activity at 0.164 uM | Activity at 0.369 uM | Activity at 0.461 uM | Activity at 0.737 uM | Activity at 0.922 uM | Activity at 1.840 uM | Activity at 2.300 uM | Activity at 3.690 uM | Activity at 4.610 uM | Activity at 9.231 uM | Activity at 20.57 uM | Activity at 46.10 uM | Activity at 92.20 uM | Compound QC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inactive | 4 | 0 0 0 0 0 | 27.0569 | 9.9398 | 10.1515 | 0.1671 | 5.5721 | 27.0569 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 1 | -4.9362 | -9.414 | 12.0824 | -11.0493 | -7.696 | -4.9362 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 1 | 5.9595 | 4.342 | -1.5624 | -2.6449 | -8.9538 | 5.9595 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -19.7473 | -1.448 | 7.5701 | -38.1554 | -17.3097 | -19.7473 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -1.2351 | -5.5487 | -5.0573 | -16.6211 | 2.7653 | -1.2351 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | 7.1959 | -7.7682 | 4.4899 | 3.3992 | 13.3707 | 7.1959 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 1 | 8.9833 | 15.335 | 4.2535 | 4.1946 | -14.3236 | 8.9833 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | 7.9022 | -10.5174 | 13.4936 | -10.4686 | 7.2323 | 7.9022 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -11.8347 | 12.2839 | -2.7256 | -19.2666 | -5.8034 | -11.8347 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inhibitor | 35.4813 | 106.2444 | Single point of activity | -4.45 | 4.4495 | 0.9934 | -109.7251 | -3.4808 | -3 | 0 0 0 0 0 | -84.6645 | -7.4849 | -2.0755 | -4.8114 | 0.1432 | -84.6645 | QC'd by "Asinex Ltd." | ||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -3.6 | -2.0717 | 4.9414 | 15.4055 | -0.2463 | -3.6 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | 0.7641 | 0 | 28.3456 | 12.1698 | 0.9078 | 0.7641 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 1 | -3.7338 | -9.9559 | 0.3986 | 8.9255 | 12.5033 | -3.7338 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -1.7797 | 3.883 | 1.182 | -4.185 | 1.7497 | -1.7797 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inhibitor | 15.8489 | 38.9608 | Single point of activity | -4.8 | 3.6772 | 0.9889 | -35.4608 | 3.5 | -3 | 0 0 0 0 0 | -32.884 | 2.0677 | 5.819 | 2.7318 | -1.3119 | -32.884 | QC'd by "Asinex Ltd." | ||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -3.797 | 8.4821 | -2.1836 | 12.76 | 5.4907 | -3.797 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -18.7499 | 1.0272 | 3.815 | 20.5199 | 1.7606 | -18.7499 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | 0.464 | 0 | 9.4101 | -6.5206 | 0.9067 | 0.464 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | 0.2371 | 9.7122 | -4.6112 | -6.6419 | -3.2889 | 0.2371 | QC'd by "Asinex Ltd." | ||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 1 | 3.6799 | 4.8924 | 1.7621 | -1.6686 | -4.4945 | 3.6799 | QC'd by "Asinex Ltd." |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| CC50 | = | 10 | ug.mL-1 |
| Standard Type | Activity Comment |
|---|---|
| Activity | Non-toxic |
| Standard Type | Activity Comment |
|---|---|
| Activity | Non-toxic |
| Standard Type | Activity Comment |
|---|---|
| Activity | Non-toxic |
| Phenotype | Potency | Efficacy | Analysis Comment | Activity_Score | Curve_Description | Fit_LogAC50 | Fit_HillSlope | Fit_R2 | Fit_InfiniteActivity | Fit_ZeroActivity | Fit_CurveClass | Excluded_Points | Max_Response | Activity at 0.0000040000 uM | Activity at 0.0000163452 uM | Activity at 0.0000320000 uM | Activity at 0.0000806082 uM | Activity at 0.0001439601 uM | Activity at 0.0003895389 uM | Activity at 0.0007288991 uM | Activity at 0.00154 uM | Activity at 0.00290 uM | Activity at 0.00454 uM | Activity at 0.00833 uM | Activity at 0.021 uM | Activity at 0.041 uM | Activity at 0.095 uM | Activity at 0.199 uM | Activity at 0.321 uM | Activity at 0.689 uM | Activity at 1.028 uM | Activity at 2.684 uM | Activity at 5.101 uM | Activity at 10.05 uM | Activity at 24.85 uM | Activity at 39.21 uM | Activity at 78.39 uM | Activity at 125.0 uM | Compound QC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inactive | 0 | 0 | 0 | 4 | 58.4116 | 43.5916 | 25.8843 | 33.4207 | 9.1109 | 21.6395 | 45.6886 | 10.8911 | 28.3955 | 31.3127 | 38.9914 | 41.6558 | 58.4116 | QC'd by Sytravon | |||||||||||||||||||||
| Inactive | 0 | 0 | 0 | 4 | -12.6805 | -10.7548 | -9.5107 | -10.6418 | -15.9997 | -12.6805 | QC'd by Sytravon | ||||||||||||||||||||||||||||
| Inactive | 0 | 0 | 0 | 4 | -7.1462 | -9.2235 | -11.8601 | -6.118 | -12.2196 | -7.1462 | QC'd by Sytravon | ||||||||||||||||||||||||||||
| Inactive | 0 | -4.75 | 4.9549 | 0.6661 | -22.0013 | -2 | 4 | 0 0 0 0 0 | -18.751 | -10.987 | -0.9935 | 2.356 | 1.2583 | -18.751 | QC'd by Sytravon | ||||||||||||||||||||||||
| Inactive | 0 | 0 | 0 | 4 | -11.1249 | -10.2692 | -11.5229 | -11.032 | -13.325 | -11.1249 | QC'd by Sytravon | ||||||||||||||||||||||||||||
| Inactive | 0 | -4.8 | 1.8851 | 0.5555 | -23.9168 | -5.4088 | 4 | 0 0 0 0 0 | -18.264 | -13.0121 | -2.8407 | -6.6548 | -7.1687 | -18.264 | QC'd by Sytravon | ||||||||||||||||||||||||
| Inactive | 0 | -6.35 | 4.9549 | 0.9083 | -3.1815 | -14.9283 | 4 | 0 0 0 0 1 | -10.2909 | -13.1276 | -17.0236 | -1.4012 | -4.6174 | -10.2909 | QC'd by Sytravon | ||||||||||||||||||||||||
| Inactive | 0 | -5.95 | 0.4 | 0.9812 | -20.7272 | -0.9942 | 4 | 0 0 0 0 0 | -16.0227 | -4.9952 | -8.1266 | -9.7286 | -14.3153 | -16.0227 | QC'd by Sytravon | ||||||||||||||||||||||||
| Inactive | 0 | -6.5 | 4.9549 | 0.6409 | -9.2158 | -16.6011 | 4 | 0 0 0 0 1 | -12.7654 | -16.3342 | -16.1896 | -6.0131 | -13.084 | -12.7654 | QC'd by Sytravon | ||||||||||||||||||||||||
| Inactive | 0 | 0 | 0 | 4 | 1.975 | 2.6103 | 3.4198 | -3.4748 | 1.7624 | 1.975 | QC'd by Sytravon | ||||||||||||||||||||||||||||
| Inactive | 0 | 0 | 0 | 4 | -8.2223 | -0.1456 | -4.3339 | -1.582 | -3.6253 | -8.2223 | QC'd by Sytravon | ||||||||||||||||||||||||||||
| Inactive | 0 | -7.25 | 4.9549 | 0.602 | -10.0715 | 2 | 4 | 0 0 0 0 0 | -12.6011 | 0.2325 | -14.2262 | -4.5441 | -8.7364 | -12.6011 | QC'd by Sytravon | ||||||||||||||||||||||||
| Inactive | 0 | -4.75 | 4.5045 | 0.9809 | -24.6554 | -10.8442 | 4 | 0 0 0 0 0 | -22.2129 | -9.8702 | -10.3098 | -11.7375 | -10.6121 | -22.2129 | QC'd by Sytravon | ||||||||||||||||||||||||
| Inactive | 0 | -4.75 | 4.9549 | 0.8409 | -13.5514 | 2 | 4 | 0 0 0 0 0 | -11.2928 | -1.9276 | 4.6106 | 1.3336 | 4.0275 | -11.2928 | QC'd by Sytravon | ||||||||||||||||||||||||
| Inactive | 0 | -5.2 | 0.5 | 0.9077 | -28.8252 | -9.4452 | 4 | 0 0 0 0 0 | -23.1876 | -10.7877 | -12.0613 | -16.7104 | -16.3414 | -23.1876 | QC'd by Sytravon | ||||||||||||||||||||||||
| Inactive | 0 | 0 | 0 | 4 | -18.3436 | -16.2788 | -21.7212 | -19.8613 | -16.6894 | -18.3436 | QC'd by Sytravon | ||||||||||||||||||||||||||||
| Inactive | 0 | 0 | 0 | 4 | -5.4025 | -9.518 | -0.1694 | 0.2848 | -4.8162 | -5.4025 | QC'd by Sytravon | ||||||||||||||||||||||||||||
| Inactive | 0 | 0 | 0 | 4 | -23.1229 | -14.0834 | -13.5556 | -16.7644 | -18.8145 | -23.1229 | QC'd by Sytravon | ||||||||||||||||||||||||||||
| Inactive | 0 | -4.95 | 3.2975 | 0.9426 | -35.5663 | -15.2262 | 4 | 0 0 0 0 0 | -34.2687 | -12.6885 | -18.3414 | -14.0693 | -16.4909 | -34.2687 | QC'd by Sytravon | ||||||||||||||||||||||||
| Inactive | 0 | -4.75 | 4.9549 | 0.7952 | -15.6253 | -4.8932 | 4 | 0 0 0 0 0 | -13.8544 | -4.3645 | -8.5252 | -3.661 | -3.9903 | -13.8544 | QC'd by Sytravon |
| Standard Type | Activity Comment |
|---|---|
| Activity | Non-toxic |
| Standard Type | Activity Comment |
|---|---|
| Activity | Dose-dependent effect |
| Standard Type | Activity Comment |
|---|---|
| Activity | Non-toxic |
| Standard Type | Standard Relation | Standard Value |
|---|---|---|
| Selectivity Index | = | 250 |
| Selectivity Index | = | 1080 |
| Selectivity Index | > | 222 |
| Selectivity Index | = | 22 |
| Selectivity Index | = | 82 |
| Selectivity Index | = | 54 |
| Selectivity Index | = | 22 |
| Selectivity Index | = | 40 |
| Selectivity Index | = | 26 |
| Selectivity Index | = | 11 |
| Selectivity Index | = | 22 |
| Selectivity Index | = | 120 |
| Selectivity Index | = | 61 |
| Selectivity Index | = | 28 |
| Selectivity Index | = | 29 |
| Selectivity Index | = | 6 |
| Selectivity Index | = | 17 |
| Selectivity Index | = | 140 |
| Selectivity Index | = | 7 |
| Selectivity Index | = | 14 |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Dose-dependent effect |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 0.288 | IC50 | = | 288 | nM |
| 0.042 | IC50 | = | 42 | nM |
| 0.029 | IC50 | = | 29 | nM |
| 0.047 | IC50 | = | 47 | nM |
| 0.061 | IC50 | = | 61 | nM |
| 0.371 | IC50 | = | 371 | nM |
| 0.106 | IC50 | = | 106 | nM |
| 0.446 | IC50 | = | 446 | nM |
| 0.26 | IC50 | = | 260 | nM |
| 1.98 | IC50 | = | 1980 | nM |
| 0.179 | IC50 | = | 179 | nM |
| 0.086 | IC50 | = | 86 | nM |
| 0.232 | IC50 | = | 232 | nM |
| 0.354 | IC50 | = | 354 | nM |
| 0.134 | IC50 | = | 134 | nM |
| 0.047 | IC50 | = | 47 | nM |
| 0.106 | IC50 | = | 106 | nM |
| 0.09 | IC50 | = | 90 | nM |
| 0.883 | IC50 | = | 883 | nM |
| 0.224 | IC50 | = | 224 | nM |
| Standard Type | Activity Comment |
|---|---|
| Activity | Active |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 5.8 | ED50 | = | 5800 | nM |
| 15 | ED50 | = | 15000 | nM |
| 8.6 | ED50 | = | 8600 | nM |
| 10.1 | ED50 | = | 10100 | nM |
| 29.9 | ED50 | > | 29900 | nM |
| 13.8 | ED50 | = | 13800 | nM |
| 9.8 | ED50 | = | 9800 | nM |
| 14.8 | ED50 | = | 14800 | nM |
| 10.6 | ED50 | = | 10600 | nM |
| 31.3 | ED50 | > | 31300 | nM |
| 9.21 | ED50 | = | 9210 | nM |
| 16.1 | ED50 | = | 16100 | nM |
| 3.7 | ED50 | = | 3700 | nM |
| 14.1 | ED50 | = | 14100 | nM |
| 17.5 | ED50 | = | 17500 | nM |
| 7.1 | ED50 | = | 7100 | nM |
| 10.1 | ED50 | = | 10100 | nM |
| 4.9 | ED50 | = | 4900 | nM |
| 17.8 | ED50 | = | 17800 | nM |
| 8.4 | ED50 | = | 8400 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 0.257 | IC50 | = | 257 | nM |
| 0.067 | IC50 | = | 67 | nM |
| 0.105 | IC50 | = | 105 | nM |
| 0.135 | IC50 | = | 135 | nM |
| 0.164 | IC50 | = | 164 | nM |
| 0.347 | IC50 | = | 347 | nM |
| 0.375 | IC50 | = | 375 | nM |
| 1.4 | IC50 | = | 1400 | nM |
| 0.088 | IC50 | = | 88 | nM |
| 0.948 | IC50 | = | 948 | nM |
| 0.306 | IC50 | = | 306 | nM |
| 0.263 | IC50 | = | 263 | nM |
| 0.623 | IC50 | = | 623 | nM |
| 0.825 | IC50 | = | 825 | nM |
| 0.609 | IC50 | = | 609 | nM |
| 0.193 | IC50 | = | 193 | nM |
| 0.728 | IC50 | = | 728 | nM |
| 0.259 | IC50 | = | 259 | nM |
| 1.59 | IC50 | = | 1590 | nM |
| 0.11 | IC50 | = | 110 | nM |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Dose-dependent effect |
| Standard Type | Standard Relation | Standard Value |
|---|---|---|
| Selectivity Index | = | 5460 |
| Selectivity Index | = | 465 |
| Selectivity Index | > | 285 |
| Selectivity Index | = | 20 |
| Selectivity Index | = | 300 |
| Selectivity Index | = | 76 |
| Selectivity Index | = | 60 |
| Selectivity Index | = | 37 |
| Selectivity Index | = | 92 |
| Selectivity Index | = | 33 |
| Selectivity Index | = | 35 |
| Selectivity Index | = | 40 |
| Selectivity Index | = | 186 |
| Selectivity Index | = | 54 |
| Selectivity Index | = | 72 |
| Selectivity Index | = | 16 |
| Selectivity Index | = | 40 |
| Selectivity Index | = | 95 |
| Selectivity Index | = | 110 |
| Selectivity Index | = | 79 |
| NCGC sample number | Sample Name | Supplier | AC50 (uM) | Curve Class2 | Efficacy | Channel |
|---|---|---|---|---|---|---|
| 4 | trans-Aconitic acid | Specs | 0.631 | 4 | -10.976 | Green |
| 10 | NEROL | Microsource | 12.5893 | 4 | -28.228 | Green |
| 3 | Phenol red | Labotest | 0.7079 | 4 | 19.263 | Green |
| 4 | Aminoquinuride dihydrochloride | Labotest | 0.7079 | 4 | 18 | Green |
| 3 | Pyridoxamine Dihydrochloride | Bosche | 15.8489 | 4 | -11.767 | Green |
| 7 | Carzenide | Labotest | 0.631 | 4 | 11.002 | Green |
| 9 | Pridinol | Specs | 10 | 2.2 | 36.664 | Green |
| 3 | L-Leucine | Bosche | 0.8913 | 4 | 14.333 | Green |
| 6 | Fenticlor | Vitas | 3.1623 | 4 | -28.657 | Green |
| 6 | CHLORPROTHIXENE HYDROCHLORIDE | Microsource | 39.8107 | -3 | -98.319 | Green |
| 8 | Benzbromarone | Labotest | 1.7783 | 4 | 16.5 | Green |
| 8 | Phosphonoacetic acid | SIGMA | 1 | 4 | -15.333 | Green |
| 17 | Domperidone | Microsource | 25.1189 | 2.3 | 125.472 | Green |
| 4 | Pifexole | Bionet | 0.631 | 4 | -9.778 | Green |
| 15 | WY-14643 | SIGMA | 3.9811 | 4 | 19.845 | Green |
| 14 | OXAPROZIN | Microsource | 39.8107 | 4 | 18.153 | Green |
| 6 | Topotecan hydrochloride | Prestwick | 31.6228 | 5 | 1429.488 | Green |
| 12 | AZELAIC ACID | Microsource | 10 | 4 | 17.221 | Green |
| 13 | Amoxapine | Enzo | 8.9125 | 2.3 | 94.86 | Green |
| 14 | R-(+)-Atenolol | Vitas | 10 | 4 | -16.344 | Green |
| NCGC sample number | Sample Name | Supplier | AC50 (uM) | Curve Class2 | Efficacy | Channel |
|---|---|---|---|---|---|---|
| 4 | trans-Aconitic acid | Specs | 4 | 0 | ratio | |
| 10 | NEROL | Microsource | 0.631 | 4 | -18.609 | ratio |
| 3 | Phenol red | Labotest | 8.9125 | 4 | 11.059 | ratio |
| 4 | Aminoquinuride dihydrochloride | Labotest | 19.9526 | 2.3 | 95.842 | ratio |
| 3 | Pyridoxamine Dihydrochloride | Bosche | 44.6684 | 4 | -13.116 | ratio |
| 7 | Carzenide | Labotest | 4 | 0 | ratio | |
| 9 | Pridinol | Specs | 28.1838 | 2.3 | 104.274 | ratio |
| 3 | L-Leucine | Bosche | 0.7943 | 4 | -27.61 | ratio |
| 6 | Fenticlor | Vitas | 15.8489 | 2.4 | 59.259 | ratio |
| 6 | CHLORPROTHIXENE HYDROCHLORIDE | Microsource | 3.1623 | 1.3 | 70.654 | ratio |
| 8 | Benzbromarone | Labotest | 7.9433 | 4 | 19.539 | ratio |
| 8 | Phosphonoacetic acid | SIGMA | 7.9433 | 4 | 9.28 | ratio |
| 17 | Domperidone | Microsource | 25.1189 | 3 | 87.928 | ratio |
| 4 | Pifexole | Bionet | 3.5481 | 4 | -20.543 | ratio |
| 15 | WY-14643 | SIGMA | 3.9811 | -3 | -98.934 | ratio |
| 14 | OXAPROZIN | Microsource | 39.8107 | 4 | 16.681 | ratio |
| 6 | Topotecan hydrochloride | Prestwick | 7.9433 | 2.1 | 83.464 | ratio |
| 12 | AZELAIC ACID | Microsource | 4 | 0 | ratio | |
| 13 | Amoxapine | Enzo | 10 | 2.1 | 101.678 | ratio |
| 14 | R-(+)-Atenolol | Vitas | 4 | 0 | ratio |
| NCGC sample number | Sample Name | Supplier | AC50 (uM) | Curve Class2 | Efficacy | Channel |
|---|---|---|---|---|---|---|
| 4 | trans-Aconitic acid | Specs | 10 | 4 | -14.43 | blue |
| 10 | NEROL | Microsource | 4 | 0 | blue | |
| 3 | Phenol red | Labotest | 39.8107 | 4 | -13.607 | blue |
| 4 | Aminoquinuride dihydrochloride | Labotest | 22.3872 | 2.3 | 95.429 | blue |
| 3 | Pyridoxamine Dihydrochloride | Bosche | 4 | 0 | blue | |
| 7 | Carzenide | Labotest | 4 | 0 | blue | |
| 9 | Pridinol | Specs | 31.6228 | 3 | 98.957 | blue |
| 3 | L-Leucine | Bosche | 0.3981 | -1.4 | -35.007 | blue |
| 6 | Fenticlor | Vitas | 10 | 2.2 | 51.546 | blue |
| 6 | CHLORPROTHIXENE HYDROCHLORIDE | Microsource | 3.1623 | 1.3 | 90.071 | blue |
| 8 | Benzbromarone | Labotest | 11.2202 | 4 | 18.74 | blue |
| 8 | Phosphonoacetic acid | SIGMA | 7.9433 | 4 | 11.21 | blue |
| 17 | Domperidone | Microsource | 39.8107 | 3 | 90.852 | blue |
| 4 | Pifexole | Bionet | 3.5481 | 4 | -15.204 | blue |
| 15 | WY-14643 | SIGMA | 3.9811 | -3 | -135.758 | blue |
| 14 | OXAPROZIN | Microsource | 44.6684 | 4 | 8.931 | blue |
| 6 | Topotecan hydrochloride | Prestwick | 0.631 | 4 | -18.88 | blue |
| 12 | AZELAIC ACID | Microsource | 1.122 | 4 | -15.036 | blue |
| 13 | Amoxapine | Enzo | 14.1254 | 2.1 | 90.875 | blue |
| 14 | R-(+)-Atenolol | Vitas | 4 | 0 | blue |
| NCGC sample number | Sample Name | Supplier | Ac50 | Curve Class | Efficacy | Channel | channel type | Conc0 | Conc1 | Conc2 | Conc3 | Conc4 | Conc5 | Conc 6 | Conc 7 | Conc8 | Conc9 | Conc10 | Data0 | Data1 | Data2 | Data3 | Data4 | Data5 | Data6 | Data7 | Data8 | Data9 | Data10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | CHLORPROTHIXENE HYDROCHLORIDE | Microsource | 12.1866164648 | 1.1 | 92.525 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 12.30727938 | 1.66740157 | -8.60949752 | 12.72087064 | -2.7243854 | -3.38567129 | 12.00564918 | -9.91213103 | 17.84040439 | 71.67526185 | 90.77331084 |
| 6 | Topotecan hydrochloride | Prestwick | 27.2824358873 | -2.1 | -112.438 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 1.02426462 | 7.86334618 | 10.10001086 | 12.07466626 | 13.7620061 | 0 | 7.34443997 | -8.66292185 | -5.19161826 | -17.9872574 | -99.87167935 |
| 15 | AMITRIPTYLINE HYDROCHLORIDE | Microsource | 17.2140532984 | 2.1 | 90.689 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 8.72733779 | 15.59760485 | 9.83442291 | 13.75408191 | -8.99522632 | 3.16379415 | 4.38999764 | 4.91273812 | 10.6641616 | 59.83678738 | 90.7252545 |
| 11 | Bepridil | BIOMOL | 4.8515793994 | 1.1 | 102.732 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -3.82099014 | -4.73176 | -4.24173872 | -7.67674444 | -11.39395334 | -5.41809653 | -12.9335455 | -0.30648697 | 68.8849268 | 94.22953292 | 96.97385658 |
| 12 | Cyproheptadine hydrochloride | Vitas | 19.3144854741 | 2.1 | 94.02 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -9.52614661 | -9.20611185 | -7.93645316 | -6.14430961 | -8.23373785 | -8.2045973 | -8.91841286 | -2.04303343 | -8.0578721 | 37.72499249 | 85.16222209 |
| 12 | Chloroquine | Specs | 13.673608569 | 2.2 | 96.493 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -16.70523463 | -17.48068886 | -18.95838922 | -23.31351868 | -12.06153491 | 4.63116408 | -5.16543274 | -3.8308893 | 10.75482058 | 44.18685112 | 65.17400712 |
| 13 | Clomipramine hydrochloride | Microsource | 6.8530380524 | 1.1 | 69.603 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 15.12022925 | 13.75008462 | 17.30042646 | 21.85386962 | 21.73302613 | 21.27848409 | 8.00675921 | 20.3551094 | 43.97725535 | 80.12274891 | 80.6695532 |
| 11 | Fluspirilene | SIGMA | 5.4435616186 | 1.1 | 95.413 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 1.20984388 | -0.4087345 | -11.3323492 | -1.05072116 | -10.8977972 | -1.58202488 | -9.4825636 | -5.39151218 | 53.20680202 | 93.36375197 | 87.43160599 |
| 13 | Imipramine..HCl | Enzo | 10.8613333569 | 2.2 | 101.143 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 1.88736483 | -17.45511617 | -16.77643702 | -3.69211985 | -23.2821796 | -23.1613361 | -21.99928296 | -15.47248053 | 21.29327614 | 52.53332598 | 79.82239516 |
| 13 | Nocodazole | SigmaAldrich | 0.4851579399 | 1.2 | 68.368 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -11.28407498 | -5.14838428 | -4.4649416 | -5.66585519 | -3.52852985 | -2.93183374 | 46.61049032 | 57.25900873 | 62.47433329 | 64.07939568 | 63.76801057 |
| 9 | Mitoxantrone | Microsource | 6.8530380524 | 2.2 | 95.462 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -15.31854296 | -14.19184031 | -15.67856632 | -23.45968415 | -22.19897559 | -21.1062445 | -5.6064363 | 14.91364203 | 21.69391495 | 43.2371516 | 66.24806011 |
| 15 | Maprotiline hydrochloride | Vitas | 3.4346551834 | 1.2 | 88.703 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -6.28486473 | -4.5085656 | -7.12801137 | -0.60948245 | -7.12525353 | -9.89788474 | 1.71612809 | 27.92713288 | 51.29731261 | 78.05085957 | 78.81352745 |
| 11 | Niclosamide | Vitas | 2.9831694393 | 1.1 | 91.606 | blue | used to calculate ratio | 4.8666666666E-4 | 0.0014599425287 | 0.0043797701149 | 0.013139310344 | 0.039417873563 | 0.11825362068 | 0.35476091954 | 1.0642827011 | 3.1928480459 | 9.5785440804 | 28.735632183 | 15.49842475 | 2.93961644 | 9.91468722 | 17.49940888 | 7.55737045 | 2.95623167 | -2.87622298 | 19.247586 | 55.62009931 | 91.29937437 | 94.84685237 |
| 5 | Octoclothepin maleate salt | SIGMA | 8.6274637521 | 1.1 | 87.683 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 0.83612916 | 5.06968808 | 12.45323773 | 12.00104804 | 5.39918074 | 11.55115891 | 4.46821699 | 3.8462964 | 33.7322265 | 86.82297758 | 92.20196443 |
| 13 | Orphenadrine hydrochloride | Microsource | 19.3144854741 | 2.1 | 99.264 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 7.05865813 | 15.94345712 | -3.88872913 | 4.7412179 | 12.99566087 | 10.7117067 | 8.19053827 | 22.06501665 | 26.63190251 | 59.77109335 | 83.51092451 |
| 6 | Proadifen hydrochloride | Vitas | 6.1077765932 | 1.1 | 99.213 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -3.57086712 | -11.57084156 | -12.89648077 | -3.44714761 | -0.13356083 | 0.80494367 | -1.20626522 | -0.54523495 | 47.21381875 | 84.73073752 | 96.87851076 |
| 18 | Pimozide | NCGCChem | 13.673608569 | 1.1 | 92.971 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -5.90377229 | -5.99681755 | -4.22371759 | -8.52028655 | -0.90361253 | -4.66581034 | -5.37476914 | -1.95101065 | -1.12715119 | 71.47690164 | 88.23271537 |
| 15 | Propafenone hydrochloride | SigmaAldrich | 10.8613333569 | 1.1 | 94.738 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -7.63294665 | -5.87093814 | -6.71082552 | 5.07993973 | -11.61100428 | -11.90107882 | -4.24820051 | -16.44725131 | 11.60072506 | 62.86720002 | 80.47901159 |
| 13 | PERPHENAZINE | Microsource | 7.6892351628 | 1.1 | 112.428 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -2.86868222 | -20.50689212 | -2.80503313 | -3.76181438 | -2.93233131 | -11.5496252 | -10.01412294 | -0.72340126 | 38.01511985 | 94.96878255 | 101.46431242 |
| 12 | PROMAZINE HYDROCHLORIDE | Microsource | 13.673608569 | 2.1 | 119.025 | blue | used to calculate ratio | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -5.0930772 | -13.73018155 | -13.8449544 | -5.1541701 | -11.39139715 | -6.826045 | -7.85465514 | -0.90233444 | 15.78037231 | 67.47953452 | 97.18857639 |
| NCGC sample number | Sample Name | Supplier | Ac50 | Curve Class | Efficacy | Channel | channel type | Conc0 | Conc1 | Conc2 | Conc3 | Conc4 | Conc5 | Conc 6 | Conc 7 | Conc8 | Conc9 | Conc10 | Data0 | Data1 | Data2 | Data3 | Data4 | Data5 | Data6 | Data7 | Data8 | Data9 | Data10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | CHLORPROTHIXENE HYDROCHLORIDE | Microsource | 12.1866164648 | 2.1 | 105.487 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 0.29304029 | -3.6996337 | -5.45787546 | 7.76556777 | -6.88644689 | -0.54945055 | 1.64835165 | -3.62637363 | 16.73992674 | 77.54578755 | 96.22710623 |
| 6 | Topotecan hydrochloride | Prestwick | 3.8537465 | 1.1 | 109.075 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 1.9047619 | 5.64102564 | 6.04395604 | 15.34798535 | 15.82417582 | 1.57509158 | 21.79487179 | 38.02197802 | 77.61904762 | 107.36263736 | 104.28571429 |
| 15 | AMITRIPTYLINE HYDROCHLORIDE | Microsource | 15.3420411513 | 2.1 | 105.869 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 0.07326007 | 7.87545788 | 3.40659341 | 6.95970696 | -6.9047619 | -0.87912088 | -1.06227106 | 8.02197802 | 14.7985348 | 69.19413919 | 98.53479853 |
| 11 | Bepridil | BIOMOL | 4.8515793994 | 1.1 | 101.17 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 0.47619048 | -1.7032967 | 1.0989011 | -7.06959707 | -5.12820513 | -0.76923077 | -2.72893773 | 3.15018315 | 74.57875458 | 96.84981685 | 100.76923077 |
| 12 | Cyproheptadine hydrochloride | Vitas | 17.2140532984 | 2.1 | 107.012 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -7.14285714 | -6.59340659 | -7.98534799 | 1.46520147 | -2.89377289 | -0.2014652 | -4.65201465 | -3.80952381 | 6.88644689 | 56.73992674 | 96.04395604 |
| 12 | Chloroquine | Specs | 15.3420411513 | 2.2 | 101.19 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -12.1836926 | -11.58388004 | -2.7366448 | -0.52483599 | -0.37488285 | 1.12464855 | -2.58669166 | 8.35988754 | 20.76850984 | 52.74601687 | 74.60168697 |
| 13 | Clomipramine hydrochloride | Microsource | 7.6892351628 | 1.1 | 72.21 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 25.04217432 | 23.46766635 | 18.1443299 | 25.15463918 | 27.89128397 | 22.19306467 | 26.12933458 | 26.12933458 | 49.78444236 | 92.55857545 | 87.9475164 |
| 11 | Fluspirilene | SIGMA | 4.8515793994 | 1.1 | 95.751 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 8.24175824 | -0.36630037 | 3.22344322 | -5.38461538 | -5.82417582 | 4.65201465 | -0.56776557 | 9.34065934 | 67.65567766 | 102.96703297 | 87.91208791 |
| 13 | Imipramine..HCl | Enzo | 12.1866164648 | 2.1 | 99.682 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -10.79662605 | -1.34957826 | -14.05810684 | -4.94845361 | -13.34582943 | -6.2230553 | -1.04967198 | -9.14714152 | 20.131209 | 58.03186504 | 83.14901593 |
| 13 | Nocodazole | SigmaAldrich | 0.5443561619 | 1.2 | 85.26 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -11.80880975 | -10.12183693 | -0.41237113 | -6.59793814 | -10.1968135 | -11.24648547 | 51.99625117 | 70.96532334 | 76.81349578 | 78.20056232 | 79.21274602 |
| 9 | Mitoxantrone | Microsource | 6.1077765932 | 1.2 | 45.099 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -3.89878163 | -7.76007498 | -3.71134021 | -10.79662605 | 0 | -14.05810684 | -11.50890347 | -6.11059044 | 15.85754452 | 39.40018744 | 34.00187441 |
| 15 | Maprotiline hydrochloride | Vitas | 3.4346551834 | 1.1 | 101.079 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -2.51171509 | -13.72071228 | -6.52296157 | -5.28584817 | -8.05998126 | -10.83411434 | -8.77225867 | 23.91752577 | 64.40487348 | 85.54826617 | 94.24554827 |
| 11 | Niclosamide | Vitas | 2.6587525614 | 1.1 | 78.368 | ratio | Confirmation | 4.8666666666E-4 | 0.0014599425287 | 0.0043797701149 | 0.013139310344 | 0.039417873563 | 0.11825362068 | 0.35476091954 | 1.0642827011 | 3.1928480459 | 9.5785440804 | 28.735632183 | 7.76556777 | 0.18315018 | 6.19047619 | 7.03296703 | 5.78754579 | 2.1978022 | -5.09157509 | 11.97802198 | 49.67032967 | 79.34065934 | 81.46520147 |
| 5 | Octoclothepin maleate salt | SIGMA | 7.6892351628 | 1.1 | 100.034 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -6.08058608 | -7.06959707 | -0.65934066 | 8.57142857 | 4.46886447 | 4.57875458 | 3.95604396 | 2.78388278 | 36.84981685 | 92.49084249 | 99.19413919 |
| 13 | Orphenadrine hydrochloride | Microsource | 19.3144854741 | 2.1 | 115.424 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | 1.06227106 | 11.46520147 | -3.33333333 | 6.996337 | 9.56043956 | 7.69230769 | 8.27838828 | 21.20879121 | 29.52380952 | 64.76190476 | 91.64835165 |
| 6 | Proadifen hydrochloride | Vitas | 4.8515793994 | 1.1 | 94.318 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -7.06959707 | -4.61538462 | -5.71428571 | -7.91208791 | -1.63003663 | 2.52747253 | 1.17216117 | 11.53846154 | 52.45421245 | 88.71794872 | 87.76556777 |
| 18 | Pimozide | NCGCChem | 10.8613333569 | 1.1 | 118.677 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -2.30769231 | -6.41025641 | -4.63369963 | -6.37362637 | 4.3956044 | -4.90842491 | -3.60805861 | 3.62637363 | 16.66666667 | 97.21611722 | 112.82051282 |
| 15 | Propafenone hydrochloride | SigmaAldrich | 7.6892351628 | 1.1 | 95.427 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -2.13683224 | -11.9212746 | -9.63448922 | -11.02155576 | -3.93626992 | -8.50984067 | -9.14714152 | -6.29803187 | 27.47891284 | 77.93814433 | 86.03561387 |
| 13 | PERPHENAZINE | Microsource | 4.3239746911 | 2.2 | 68.763 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -5.87912088 | -20.78754579 | -7.43589744 | -11.00732601 | -15.32967033 | -13.64468864 | -6.31868132 | -3.33333333 | 39.5970696 | 93.62637363 | 56.15384615 |
| 12 | PROMAZINE HYDROCHLORIDE | Microsource | 15.3420411513 | 2.1 | 115.757 | ratio | Confirmation | 9.7327586206E-4 | 0.0029198275862 | 0.0087595402298 | 0.026278563218 | 0.078835747126 | 0.23650724137 | 0.7095217816 | 2.1285653448 | 6.3856960344 | 19.157088103 | 57.471264367 | -13.75457875 | -20.64102564 | -19.72527473 | -16.79487179 | -8.36996337 | -5.6959707 | -3.75457875 | -2.8021978 | 3.18681319 | 58.57142857 | 93.80952381 |